RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in Biotech

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the best drug stocks to buy according to analysts. On April 7, RBC Capital lifted the price target on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to $14 from $13 while maintaining an Outperform rating on the shares. The rating update came as part of a broader research note by the firm previewing fiscal Q1 results in Biotech. It told investors in the research note that seasonal headwinds around gross/net, reimbursement resets, and fewer selling days may be exacerbated in fiscal Q1 by weather impact, especially for launching and in-clinic products. However, it also stated that the robust return of M&A, coupled with clarity on limited tariff/Most Favored Nation drug pricing impacts, could help offset both this and broader macro volatility while keeping sector perceptions favorable.

For additional reference, in its full year 2025 results, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported ORLADEYO® net revenue of $601.8 million, up 38% year-over-year. It also maintained full-year 2026 ORLADEYO revenue guidance between $625 and $645 million.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biotechnology company that provides structure-guided drug design to develop oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.